UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 6,089	$ 7,409
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	405	327
Amortization	1,048	1,023
Provision for (recovery of) losses on accounts receivable	(7)	(6)
Amortization of Right-of-Use Assets	26	26
Deferred income taxes	(360)	(364)
Stock-based compensation expense	168	131
Tax benefit attributable to exercise of stock options	0	20
Accounts receivable and other receivables	409	(297)
Inventories	908	441
Prepaid expenses and other current assets	145	45
Accounts payable	37	66
Accrued expenses	(1,531)	(783)
Total adjustments	1,248	629
Net cash provided by operating activities	7,337	8,038
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(235)	(132)
Intangible assets	0	(5)
Proceeds from sale of property and equipment	0	27
Net cash used in investing activities	(235)	(110)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - options	0	390
Common stock purchased and retired	(6,708)	(9,393)
Payment of dividends	(2,018)	(2,170)
Net cash used in financing activities	(8,726)	(11,173)
Effect of exchange rate changes on cash	827	(404)
Net increase in cash and cash equivalents	(797)	(3,649)
Cash at beginning of period	82,976	92,868
Cash at end of period	82,179	89,219
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for income taxes	2,327	2,791
Cash paid during the period for interest	$ 0	$ 0